Keryx Makes Next Move, Files Zerenex NDA
By Marie Powers
Thursday, August 8, 2013
As expected, New York-based Keryx Biopharmaceuticals Inc. submitted a new drug application (NDA) for Zerenex (ferric citrate coordination complex) in the initial indication of treating elevated serum phosphorus levels, or hyperphosphatemia, in patients with chronic kidney disease (CKD) on dialysis.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.